Ovarian Cancer Research Alliance Community Partner

RSS News

  • Zejula Now Available in UK as Maintenance Therapy for Advanced Ovarian Cancer January 21, 2021
    The National Institute of Health and Care Excellence (NICE) has recommended the use of Zejula (niraparib) as a maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The medication will be available through the Cancer Drugs Fund (CDF), a funding program that seeks to increase access to promising cancer medicines in […]
  • UV1 Triple Combo Maintenance Therapy Will Be Tested in Phase 2 Trial January 19, 2021
    Ultimovacs will test its experimental cancer vaccine, UV1, as part of a triple-combination therapy for women with relapsed ovarian cancer who have no mutations in their BRCA DNA repair genes. The Phase 2 DOVACC collaboration study will investigate UV1, in combination with AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab) and PARP inhibitor Lynparza (olaparib), as a […]
  • GPS Vaccine-Keytruda Combo Showing Efficacy in Advanced Cancer Patients January 14, 2021
    Combining the experimental vaccine galinpepimut-S (GPS) with the immune checkpoint inhibitor Keytruda (pembrolizumab) induces promising responses in people with metastatic ovarian cancer who failed one or two prior lines of treatment, early data from a Phase 1/2 trial show. The combination kept all eight patients in a first evaluated group in the trial (NCT03761914) without signs […]
  • Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers January 12, 2021
    Lynparza (olaparib) has been approved in Japan as a maintenance treatment for women with advanced ovarian cancer who responded to a first-line chemotherapy regimen containing bevacizumab, AstraZeneca and Merck announced in a press release. The approval, for patients whose cancer is positive for homologous recombination deficiency (HRD), is based on data from the PAOLA-1 Phase 3 trial (NCT02477644), […]
  • $34M Funding Helps Speed Up New Class of Cancer Diagnostics January 7, 2021
    InterVenn Biosciences has raised $34 million to commercialize a new diagnostic tool for ovarian cancer, based on the identification of circulating proteins containing sugar molecules (glycoproteins). The company expects to validate the diagnostic tool intended for immediate clinical use and drive rapidly expanding partnership projects. The funding will also help accelerate the use of glycoproteins in […]
  • Trial Confirms Rubraca’s Clinical Benefit Over Chemotherapy January 5, 2021
    Rubraca (rucaparib) is superior to chemotherapy at prolonging life without disease worsening in people with advanced ovarian cancer who received at least two prior lines of chemotherapy, according to top-line data from an ongoing Phase 3 trial. Data from the study, called ARIEL4 (NCT02855944), also showed that Rubraca’s safety profile in these women, whose tumors contained […]
  • DPX-Survivac Responses Now Up to 16 Months in Advanced Ovarian Cancer Trial December 22, 2020
    IMV‘s immunotherapy DPX-Survivac plus low-dose chemotherapy continues to show sustained benefits in people with heavily treated advanced ovarian cancer, with some benefits lasting up to 16 months, updated findings from a Phase 1/2 clinical trial show. These data “clearly support the relevance of DPX-Survivac as a potential new and much-needed treatment option for advanced recurrent ovarian […]
  • STRO-002 Continues to Show Promise in Phase 1 Trial for Advanced Ovarian Cancer December 17, 2020
    STRO-002, Sutro Biopharma’s experimental antibody-drug conjugate, continues to be safe and elicit promising responses in heavily pretreated patients with advanced ovarian cancer, according to the latest data from a Phase 1 clinical trial. Updated interim findings from the ongoing open-label study (NCT03748186) showed that 32% of women who were eligible for response analyses responded to […]
  • $3.2M NIH Grant Supports Development of New Approach to Target ‘Invisible’ Residual Tumors December 15, 2020
    A $3.2-million grant from the National Institutes of Health has been awarded to the collaborative work between Northeastern University’s Spring Lab and Cellaria into a new method of eliminating the microscopic cancerous tumors left behind by standard therapies. The approach uses antibody-photosensitizer molecules that make cancer cells susceptible to light-induced destruction. Researchers will mainly focus […]
  • Anixa Enters License Agreement With Cleveland Clinic for Ovarian Cancer Vaccine December 10, 2020
    Anixa Biosciences has entered in a license agreement with the Cleveland Clinic to obtain the exclusive, global rights for a new ovarian cancer vaccine technology. “Through this collaboration we are expanding into additional preventive and therapeutic areas and we look forward to seeing the development of this ovarian cancer vaccine,” Vincent Tuohy, PhD, an immunologist at […]
  • Phase 2 Trial Begins Testing VS-6766, Defactinib Combo in Low-grade Serous Ovarian Cancer December 8, 2020
    Verastem Oncology has started a Phase 2 clinical trial evaluating its inhibitors, VS-6766 and defactinib, for the treatment of people with recurrent low-grade serous ovarian cancer (LGSOC), the company announced. The trial seeks to recruit up to 100 female patients — more information is available here — and will investigate the company’s RAF/MEK inhibitor VS-6766, […]
  • CRISPR-Cas9 in Lipid Nanoparticles Found to Safely Treat Ovarian Cancer in Mice December 3, 2020
    For the first time, researchers safely and effectively treated cells and mice with ovarian cancer using the CRISPR-Cas9 gene-editing tool plus a newly developed lipid nanoparticle (LNP) delivery system, which targeted and destroyed the cancer cells by genetic manipulation.  This new therapeutic strategy has the potential to treat not only other types of cancer, but […]
  • Assisted Reproductive Technology Does Not Raise Risk of Ovarian Cancer, Study Indicates December 1, 2020
    Women who use assisted reproductive technology to help them conceive a child appear not to be at an increased risk of developing ovarian cancer, a nationwide study conducted in the Netherlands has found. The study, “Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology,” was published in the Journal of the National […]
  • New $100M Program Aims to Improve Diversity in Clinical Trials November 26, 2020
    A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved patient populations. The initiative seeks to extend the reach of clinical studies to underserved populations in the nation’s urban and rural communities, and promote treatment development […]
  • ALKS 4230-Keytruda Combo Found to Reduce Tumor Size, Halt Disease Progression November 24, 2020
    The combination of Keytruda (pembrolizumab) and ALKS 4230 was able to halt disease progression and reduce tumor size in a small group of heavily pre-treated patients with advanced ovarian cancer, according to data from an ongoing Phase 1/2 trial. Findings from the trial, called ARTISTRY-1 (NCT02799095), also showed the combination therapy had a manageable safety […]